论文部分内容阅读
目的讨论血清N末端B型利钠肽原(NT-proBNP)水平与美国纽约心脏病学会(NYHA)心功能分级的相关性,为临床诊治工作提供参考。方法 100例心血管病患者为观察组,按NYHA心功能分级:Ⅰ级组25例,Ⅱ级组18例,Ⅲ级组31例,Ⅳ级组26例。选择同期来本院健康体检研究对象100例为对照组。通过对研究对象的血清NT-proBNP水平进行检测分析,了解血清NT-proBNP水平与NYHA心功能分级的相关性。结果观察组NYHA I、Ⅱ、Ⅲ、Ⅳ级的NT-proBNP水平分别为(349.88±109.65)、(450.45±192.04)、(797.48±273.88)、(1352.03±560.78)pg/ml,对照组NT-proBNP水平为(2.58±0.11)pg/ml,观察组不同NYHA分级的NT-pro BNP水平均高于对照组(P<0.05),且不同NYHA分级间NT-proBNP水平比较,差异有统计学意义(P<0.05)。结论通过对心血管病患者的血清NT-proBNP水平进行检验,可进一步对患者的心功能情况进行深入的了解,同时有助于明确患者NYHA心功能级别。对于心血管病患者而言,血清NT-proBNP水平主要是随着心力衰竭的严重程度增加,表现出不断升高的趋势。建议在今后的临床心功能NYHA分级中,将血清NT-proBNP水平检测推广应用。
Objective To discuss the correlation between serum N-terminal pro-N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac function classification of New York Heart Association (NYHA) in the United States and provide reference for clinical diagnosis and treatment. Methods 100 patients with cardiovascular disease were observed. According to NYHA functional class, 25 cases were grade Ⅰ, 18 cases were grade Ⅱ, 31 cases were Ⅲ and 26 cases were Ⅳ. Select the same period to our hospital 100 healthy subjects for the control group. Through the study of serum NT-proBNP levels were analyzed to understand the relationship between serum NT-proBNP levels and NYHA functional classification. Results The levels of NT-proBNP in NYHA class I, II, III and IV in the observation group were (349.88 ± 109.65), (450.45 ± 192.04), (797.48 ± 273.88) and (1352.03 ± 560.78) pg / (2.58 ± 0.11) pg / ml, the levels of NT-pro BNP in NYHA class were higher in the observation group than those in the control group (P <0.05), and there was significant difference in NT-proBNP levels between different NYHA classifications (P <0.05). Conclusions The level of serum NT-proBNP in patients with cardiovascular diseases can be further tested to understand the cardiac function of patients and help to clarify the NYHA functional level of patients. For patients with cardiovascular disease, serum NT-proBNP levels are mainly increasing with the severity of heart failure, showing an increasing trend. It is suggested that in the future NYHA classification of clinical cardiac function, serum NT-proBNP level should be tested and applied.